Hiroshi Shimizu

Dr. Hiroshi Shimizu

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2016 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
THTsuyoshi Hamaguchi
Tsuyoshi Hamaguchi
YTYu Taniguchi
Yu Taniguchi
KSKenji Sakai
Kenji Sakai
TKTetsuyuki Kitamoto
Tetsuyuki Kitamoto
MTMasaki Takao
Masaki Takao
MYMasahito Yamada
Masahito Yamada

1 October 2016 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
NMNoriko Miyake
Noriko Miyake
RFRyoko Fukai
Ryoko Fukai
COChihiro Ohba
Chihiro Ohba
TCTakahiro Chihara
Takahiro Chihara
MMMasayuki Miura
Masayuki Miura
NMNaomichi Matsumoto
Naomichi Matsumoto

23 June 2016 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
RTRyoko Takeuchi
Ryoko Takeuchi
MTMari Tada
Mari Tada
ASAtsushi Shiga
Atsushi Shiga
YTYasuko Toyoshima
Yasuko Toyoshima
TKTakuya Konno
Takuya Konno
HTHitoshi Takahashi
Hitoshi Takahashi
Frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS) are types of major TDP-43 (43-kDa TAR DNA-binding protein) proteinopathy. Cortical TDP-43 pathology has been analyzed in detail in cases of FTLD-TDP, but is still unclear in cases of ALS. We attempted to clarify the cortical and subcortical TDP-43 pathology in Japanese cases of sporadic ALS (n = 96) using an antibody specific to phosphorylated TDP-43 (pTDP-43). The cases were divided into two groups: those without pTDP-43-positive neuronal cytoplasmic inclusions in the hippocampal dentate granule cells (Type 1, n = 63), and those with such inclusions (Type 2, n = 33). Furthermore, the Type 2 cases were divided into two subgroups based on semi-quantitative estimation of pTDP-43-positive dystrophic neurites (DNs) in the temporal neocortex: Type 2a (accompanied by no or few DNs, n = 22) and Type 2b (accompanied by abundant DNs, n = 11). Clinico-pathologic analysis revealed that cognitive impairment was a feature in patients with Type 2a and Type 2b, but not in those with Type 1, and that importantly, Type 2b is a distinct subtype characterized by a poor prognosis despite the less severe loss of lower motor neurons, the unusual subcortical dendrospinal pTDP-43 pathology, and more prominent glial involvement in cortical pTDP-43 pathology than other two groups. Considering the patient survival time and severity of motor neuron loss in each group, transition from Type 1 to Type 2, or from Type 2a to Type 2b during the disease course appeared unlikely. Therefore, each of these three groups was regarded as an independent subtype.

28 June 2013 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
HSHiroshi Shimizu
Hiroshi Shimizu
YTYasuko Toyoshima
Yasuko Toyoshima
ASAtsushi Shiga
Atsushi Shiga
AYAkio Yokoseki
Akio Yokoseki
KAKeiko Arakawa
Keiko Arakawa
HTHitoshi Takahashi
Hitoshi Takahashi

3 June 2020 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
RSRie Saito
Rie Saito
HSHiroshi Shimizu
Hiroshi Shimizu
TMTakeshi Miura
Takeshi Miura
NHNorikazu Hara
Norikazu Hara
NMNaomi Mezaki
Naomi Mezaki
AKAkiyoshi Kakita
Akiyoshi Kakita

21 December 2012 in Neuropathology
Verified
Journal Article
Closed access
PDF file
RORyosuke Ogura
Ryosuke Ogura
HAHiroshi Aoki
Hiroshi Aoki
MNManabu Natsumeda
Manabu Natsumeda
HSHiroshi Shimizu
Hiroshi Shimizu
TKTsutomu Kobayashi
Tsutomu Kobayashi
AKAkiyoshi Kakita
Akiyoshi Kakita